Literature DB >> 12891630

Microarray analysis of xenograft-derived cancer cell lines representing multiple experimental models of human prostate cancer.

Gennadi V Glinsky1, Anja Krones-Herzig, Anna B Glinskii, Gerhard Gebauer.   

Abstract

Expression analysis of 7129 transcripts was carried out in five human prostate cancer cell lines derived from orthotopic xenografts after one to five passages in nude mice and primary cultures of human normal prostate epithelial (NPE) cells. These experiments identified a consensus class of 214 genes (43 up- and 171 downregulated transcripts), expression of which was altered at least twofold in the same direction in all the cell lines relative to NPE cells. To validate the relevance of altered expression behavior of these genes for human prostate cancer, their expression pattern was evaluated in multiple additional experimental and clinical settings. Expression of 170 of these 214 genes (79%) was altered in the same direction in vivo in experimental human prostate tumors in mice. Similarly, the expression of 151 of the 214 genes (71%) was altered in the same direction in M12 cells, a variant of an SV40 large T antigen transformed normal human prostate epithelial cell line selected for increased malignancy in vivo. In clinical samples of human prostate tumors, the changes in transcript expression levels of majority of these genes (85% of downregulated and 76% of upregulated transcripts) are consistent with alterations of their expression pattern in xenograft-derived cancer cell lines. These results imply that the expression pattern of a large class of genes is consistently altered in multiple experimental models and clinical samples of human prostate cancer and underscore the potential relevance of the xenograft models and cell lines derived from them for expression analysis studies relevant to human cancer. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12891630     DOI: 10.1002/mc.10139

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  7 in total

1.  Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders.

Authors:  Anna B Glinskii; Shuang Ma; Jun Ma; Denise Grant; Chang-Uk Lim; Ian Guest; Stewart Sell; Ralph Buttyan; Gennadi V Glinsky
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

Review 2.  Human prostate cancer heterotransplants: a review on this experimental model.

Authors:  Lluis A Lopez-Barcons
Journal:  Asian J Androl       Date:  2010-04-05       Impact factor: 3.285

3.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.

Authors:  Gennadi V Glinsky; Olga Berezovska; Anna B Glinskii
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

4.  Gene expression profiling predicts clinical outcome of prostate cancer.

Authors:  Gennadi V Glinsky; Anna B Glinskii; Andrew J Stephenson; Robert M Hoffman; William L Gerald
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

5.  Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors.

Authors:  Robert A Stull; Roya Tavassoli; Scot Kennedy; Steve Osborn; Rachel Harte; Yan Lu; Cheryl Napier; Arie Abo; Daniel J Chin
Journal:  BMC Genomics       Date:  2005-04-18       Impact factor: 3.969

6.  Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma.

Authors:  Cleo Robinson; Ian M Dick; Michael J Wise; Andrew Holloway; Dileepa Diyagama; Bruce W S Robinson; Jenette Creaney; Richard A Lake
Journal:  BMC Cancer       Date:  2015-12-18       Impact factor: 4.430

7.  Genomics-Guided Drawing of Molecular and Pathophysiological Components of Malignant Regulatory Signatures Reveals a Pivotal Role in Human Diseases of Stem Cell-Associated Retroviral Sequences and Functionally-Active hESC Enhancers.

Authors:  Gennadi V Glinsky
Journal:  Front Oncol       Date:  2021-03-31       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.